Date Title Description PDF
09 Jul 2020 On business and financial situation ROVI informs on the Collaboration with Moderna for Outside the United States Fill-Finish Manufacturing of Moderna’s COVID-19 Vaccine Candidate Download

Pages

Date Title Description PDF
08 Jul 2024 Other relevant information The Company informs about the dividends payment.   Download
04 Jul 2024 Liquidity and counterparty agreements Liquidity contract: transactions conducted in the second quarter of 2024 Download
24 Jun 2024 Announcement of General Shareholders' Meeting The Company reports on the resolutions adopted by the Ordinary General Shareholders' Meeting and by the Board of Directors. Download
11 Jun 2024 Share buy-back , stabilisation and treasury stock programmes Share Buyback Program: transactions conducted between 7 June 2024 and 11 June 2024 and end of the share buyback program Download
07 Jun 2024 Share buy-back , stabilisation and treasury stock programmes Share Buyback Program: transactions conducted between 31 May and 6 June 2024 Download

Pages

Date Title Description PDF
08 Oct 2018 Share capital increases and reductions Information on the registration in the Commercial Registry of Madrid of the notarial deed regarding the capital increase Download
05 Oct 2018 Buy-back programmes, stabilisation and treasury stock Information about the possibility that Jefferies International Limited carries out stabilisation transactions within the framework of the capital increase excluding pre-emptive subscription rights of the existing shareholders of Laboratorios Farmacéuticos Rovi, S.A. Download
04 Oct 2018 Share capital increases and reductions Directors’ Report and Independent Expert Report related to capital increase excluding preferential subscription rights Download
04 Oct 2018 Liquidity contracts and specialists The Company informs that has temporarily suspended liquidity agreement with JB Capital Markets, Sociedad de Valores, S.A.U. Download
04 Oct 2018 Share capital increases and reductions Information on price fixing and outcome of the private placement related to capital increase addressed to institutional investors, excluding preferential subscription rights Download

Pages